Wednesday, March 29, 2023


Biotechnology News Magazine


Orbit Discovery and Endevica Bio Enter Multi-target Collaboration to Advance Development of Cachexia Therapeutics

The agreement covers activities ranging from hit ID to development of cell-based assays, with an option for Endevica to further develop the peptide hits resulting from the screening activities.

SK bioscience Introduces New Partnership Model to Establish Regional Vaccine Hubs

Mr. Ahn said, "SK bioscience can transplant vaccine manufacturing facilities, technologies, and products to any countries in need based on the accumulated experiences in R&D and manufacturing we have been building. A bilateral partnership can be established if the country in need is willing to provide funds, human resources, and overall environments with collaboration of global initiatives."

Genmab Announces Net Sales of DARZALEX ® (daratumumab) for 2022

Net sales of DARZALEX ® in 2022 totaled USD 7,977 million. Genmab receives royalties on worldwide net sales from Janssen Biotech, Inc. (Janssen).

CytoReason to License Its IBD Disease Model to Sanofi in Expanded Multiyear, Multimillion Dollar Deal

Under the terms of the expanded agreement, Sanofi will pay CytoReason an undisclosed multimillion dollar amount. Sanofi has previously applied Cytoreason’s cell-centered model to better understand asthma patient subtypes.

Ubiquigent Collaborates with University of Glasgow on Translational Structural Biology to Accelerate Drug Discovery within the (de)Ubiquitylation Field

Dr Mehmet Gundogdu, Principal Scientist, Ubiquigent, commented: “Collaborating with Professor Walden on this project is an exciting opportunity to combine forces in an important therapeutic area. USP30 is a prominent target in the DUB drug discovery space, and this project has great potential to enable the structure-led design and development of novel USP30 modulators.”

Lonza Collaborates with Cristal Therapeutics and McSAF to Expand Bioconjugates Offering

The collaborations will enable the integration of two novel conjugation platforms, McSAF Inside® and CliCr®, into the Lonza Bioconjugation Toolbox